Abstract
Jerome Conn, the father of primary aldosteronism (PA), proposed that the syndrome may account for approximately 20% of patients with blood pressure (BP) elevation. For decades thereafter, conventional wisdom considered PA a rare (1%) and relatively benign form of hypertension,whichwenowknowisnotthecase.Thefirst seismic shift came with the introduction of screening for PA by the aldosterone-to-renin ratio (ARR); on this basis, followed by confirmatory/exclusion testing, it is now rec
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: The Journal of Clinical Endocrinology & Metabolism
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
